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Background
In the absence of an internationally recognised biomar-
ker of treatment response in HAM/TSP, the HAM/TSP
clinial trial study group chose improvement of 10 meter
time walk (TW) as the primary outcome measure for
the HAMLET-P trial.
Aim
To define the minimum change in TW required for an
observed treatment effect to be detectable and impor-
tant. To calculate the sample size required for 90%
power to detect this difference.
Methods
Prospectively collected TW (seconds/10m) of HAM/TSP
patients from the four countries were submitted to two
biostatisticians (Japan+UK). Analysis of covariance and
log transformed TW were used.
Results
Matched TW data (baseline+6 months) were available for
a total of 76 patients. Mean (SD,median) TW were 23.46
(±18.9,16.32) at baseline, 24.85 (±23.89,16.38) at 6 months.
Mean (SD,median) log10m TW were 2.89 (±0.72,2.79) at
baseline, 2.91 (±0.74,2.80) at 6 months. The estimated SD
of log10m TW after adjustment for the baseline measure-
ment was 0.26. With 30 participants/group, we have 90%
power to detect a difference of ±0.21. This corresponds
to a ratio of 0.81 or 1.23, so we could detect a decrease
in time of 19% or an increase of 23%. With power 80%
we could detect a difference of -15% or +18%.
Conclusions
Prospectively collected longitudinal data on TW is useful
in measuring inter- and intra- patient variability of this
clinical efficacy marker. To power HAMLET-P at 90%, a
minimum of 30 patients are needed in each arm, to be
increased by 3-5 patients/arm to cover for 10-15% esti-
mated trial drop-out rate.
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